Semaglutide

A GLP‑1 receptor agonist with proven ASCVD benefit and strong weight loss is a great candidate drug for patients with cardiovascular disease and obesity. However, it is preferred for HFpEF and it has not been shown to reduce HFrEF hospitalization. It may be added later for weight or ASCVD risk, but it does not replace another cardioprotective drug for HF benefit as a first step.

  • Further Developments

Map: Michael Green_GEMD (1114)
Node: 21075
Score:

reset

OpenLabyrinth
OpenLabyrinth is an open source educational pathway system

Review your pathway

  • 37°C, ατμοσφαιρικά επίπεδα O₂, ατμοσφαιρικά επίπεδα CO₂
  • Συνέχιση ήπιας άσκησης.
  • Matrița ADN, Primeri, ADN polimerază, rNTPs, Soluție tampon
  • Matrița ADN, ARN polimerază, dNTPs, Soluție tampon
  • Temperatura 37 ⁰C, niveluri atmosferice de O2 , 5% nivel de CO2 .
  • Molde de ADN, ARN polimerasa, dNTPs, Solución tampón
  • Molde de ADN, Cebadores, ADN polimerasa, rNTPs, Solución tampón
  • Θα γίνω ακόμη πιο ενεργός- αθλητικός.
  • Θα συνεχίσω να αθλούμαι στα ίδια επίπεδα.
  • Sitagliptin
  • DNA template, Primers, DNA polymerase, dNTPs, Buffer solution
  • Molde de ADN, Cebadores, ARN polimerasa, dNTPs, Solución tampón
  • Temperatura 37 ⁰C, niveluri atmosferice de O2 , niveluri atmosferice de CO2 .
  • Θα σταματήσω εντελώς να γυμνάζομαι.
  • Insulin detemir
  • Dapagliflozin
  • Semaglutide

Reminder

empty_reminder_msg

FINISH

Time is up